Build and internal testing of a commercial production module for astatinated radiopharmaceuticals
| Reference number | |
| Coordinator | Alpha Therapy Solutions AB |
| Funding from Vinnova | SEK 900 000 |
| Project duration | June 2021 - November 2021 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups step 2 spring 2021 |
Important results from the project
The purpose of this project was to build and analyze a prototype of a product concept that was previously developed in an Innovativa Startups Steg 1 project. The goal was to be able to develop the product to a point that it could be CE-marked and installed at the first customer site and this objective has been partially achieved. The product could be installed at the first pilot customer, but the CE marking has now been postponed until Q2 2022.
Expected long term effects
As a result of this project, we are now very close to being able to launch our first commercial product. The only process still to be completed is to CE mark the product in Q2 2022. The effect of this is that drug developers around the world will soon have access to the technology they need to develop vital cancer drugs based on the alpha emitter astatine-211. The product will enable more and larger clinical trials in this field and will play a significant role in the commercialization of these potentially life-saving cancer pharmaceuticals.
Approach and implementation
This project was carried out by Atley Solutions (formerly Alpha Therapy Solutions) together with the subcontractors FutureChemistry, Elysia-Raytest and Michael Lund, as well as the pilot customer Göteborgs Universitet. The implementation is considered largely successful. Another subcontractor (JopiTech) was hired to contribute expert expertise on the specific CE marking process required by the product.